Shell Asset Management Co. Has $688,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Shell Asset Management Co. decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) by 10.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,334 shares of the company’s stock after selling 896 shares during the period. Shell Asset Management Co.’s holdings in Neurocrine Biosciences were worth $688,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. bought a new stake in Neurocrine Biosciences in the 4th quarter valued at $37,219,000. California Public Employees Retirement System lifted its position in Neurocrine Biosciences by 199.6% in the 4th quarter. California Public Employees Retirement System now owns 628,882 shares of the company’s stock valued at $53,562,000 after acquiring an additional 418,990 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Neurocrine Biosciences by 254.3% in the 4th quarter. Point72 Asset Management L.P. now owns 527,774 shares of the company’s stock valued at $44,951,000 after acquiring an additional 378,826 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in Neurocrine Biosciences by 20.6% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,377,945 shares of the company’s stock valued at $117,360,000 after acquiring an additional 235,530 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its position in Neurocrine Biosciences by 280.2% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 309,913 shares of the company’s stock valued at $26,395,000 after acquiring an additional 228,400 shares in the last quarter. Institutional investors and hedge funds own 93.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Morgan Stanley boosted their price target on shares of Neurocrine Biosciences from $100.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Friday, July 15th. JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $125.00 to $126.00 and gave the stock an “overweight” rating in a research report on Monday, April 4th. Wedbush reissued an “outperform” rating on shares of Neurocrine Biosciences in a research report on Thursday, April 28th. Finally, Barclays boosted their price target on shares of Neurocrine Biosciences from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $112.07.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX opened at $92.03 on Tuesday. The company’s 50 day moving average price is $94.74 and its two-hundred day moving average price is $90.30. Neurocrine Biosciences, Inc. has a 12-month low of $71.88 and a 12-month high of $108.01. The firm has a market cap of $8.80 billion, a PE ratio of 127.82 and a beta of 0.59. The company has a quick ratio of 3.90, a current ratio of 4.02 and a debt-to-equity ratio of 0.27.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last announced its earnings results on Wednesday, May 4th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.19). Neurocrine Biosciences had a return on equity of 5.30% and a net margin of 5.91%. The business had revenue of $310.60 million for the quarter, compared to analyst estimates of $304.07 million. During the same quarter in the previous year, the company earned $0.33 EPS. The business’s revenue for the quarter was up 31.3% on a year-over-year basis. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 1.93 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $76.30, for a total transaction of $1,144,500.00. Following the completion of the sale, the director now owns 29,512 shares of the company’s stock, valued at approximately $2,251,765.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Julie Cooke sold 754 shares of the company’s stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $100.00, for a total transaction of $75,400.00. Following the completion of the sale, the insider now owns 16,918 shares of the company’s stock, valued at approximately $1,691,800. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $76.30, for a total transaction of $1,144,500.00. Following the sale, the director now directly owns 29,512 shares of the company’s stock, valued at approximately $2,251,765.60. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Company Profile

(Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Read More

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.